The effects of testosterone and dihydrotestosterone on hypothalamic regulation of growth hormone secretion.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone), published as a randomized controlled trial.

This was also done with pyridostigmine (PDS) pretreatment to assess the effects of somatostatin.

Why It Was Studied

It is not known whether this occurs via pituitary or hypothalamic mechanisms.

The researchers evaluated the GH secretion of 12 boys, aged 13.67 +/- 0.37 yr (mean +/- SE), diagnosed with constitutional delay in growth and adolescence.

Who Took Part

The study group was 12 boys.

By PubMed's age tags, the people studied were children and teenagers, men only.

How the Study Was Run

The design is described as randomized and double-blind.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the boys and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Pituitary responsiveness was assessed by the administration of GHRH with sampling of GH at intervals for the next 2 h.

The response to GHRH was measured as the area under the curve.

What Was Measured

The researchers evaluated the GH secretion of 12 boys, aged 13.67 +/- 0.37 yr (mean +/- SE), diagnosed with constitutional delay in growth and adolescence.

All tests were then repeated during treatment.

PubMed files the paper under topics including Dihydrotestosterone, Growth Disorders, Growth Hormone, Growth Hormone-Releasing Hormone, Hypothalamus, Pituitary Gland and Testosterone.

What This Means in Plain Language

The paper is a randomized and double-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone) in 12 boys.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1996 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.